US 10,376,568 B2
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); Harpreet Singh, Muenchen Schwabing (DE); Phillip Mueller, Kassel (DE); Julia Leibold, Langkampfen (AT); and Valentina Goldfinger, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Dec. 5, 2018, as Appl. No. 16/210,330.
Application 16/210,330 is a continuation of application No. 16/100,498, filed on Aug. 10, 2018.
Application 16/100,498 is a continuation of application No. 15/638,072, filed on Jun. 29, 2017, granted, now 10,155,032.
Application 15/638,072 is a continuation of application No. 15/229,970, filed on Aug. 5, 2016, granted, now 9,908,920, issued on Mar. 6, 2018.
Claims priority of provisional application 62/201,289, filed on Aug. 5, 2015.
Claims priority of application No. 1513921.5 (GB), filed on Aug. 6, 2015.
Prior Publication US 2019/0091311 A1, Mar. 28, 2019
Int. Cl. A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01)
CPC A61K 39/0011 (2013.01) [C07K 14/47 (2013.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12N 15/115 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5748 (2013.01); G01N 33/6848 (2013.01); A61K 38/00 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C07K 2319/00 (2013.01); C12N 2310/16 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 33/57407 (2013.01); G01N 2570/00 (2013.01); G01N 2800/52 (2013.01)] 20 Claims
 
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that aberrantly present a peptide consisting of the amino acid sequence of LYFEKGEYF (SEQ ID NO: 55),
wherein said cancer is selected from the group consisting of lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, and prostate cancer.